JP2018516911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516911A5 JP2018516911A5 JP2017561621A JP2017561621A JP2018516911A5 JP 2018516911 A5 JP2018516911 A5 JP 2018516911A5 JP 2017561621 A JP2017561621 A JP 2017561621A JP 2017561621 A JP2017561621 A JP 2017561621A JP 2018516911 A5 JP2018516911 A5 JP 2018516911A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- antagonist
- cancer
- cpg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021041014A JP7236483B2 (ja) | 2015-05-29 | 2021-03-15 | がんの処置のためのＰＤ－１アンタゴニストとＣｐＧ－Ｃ型オリゴヌクレオチドの併用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168449P | 2015-05-29 | 2015-05-29 | |
| US62/168,449 | 2015-05-29 | ||
| US201562169309P | 2015-06-01 | 2015-06-01 | |
| US62/169,309 | 2015-06-01 | ||
| PCT/US2016/034275 WO2016196173A1 (en) | 2015-05-29 | 2016-05-26 | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021041014A Division JP7236483B2 (ja) | 2015-05-29 | 2021-03-15 | がんの処置のためのＰＤ－１アンタゴニストとＣｐＧ－Ｃ型オリゴヌクレオチドの併用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516911A JP2018516911A (ja) | 2018-06-28 |
| JP2018516911A5 true JP2018516911A5 (enExample) | 2019-06-27 |
| JP6893608B2 JP6893608B2 (ja) | 2021-06-23 |
Family
ID=57441888
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561621A Active JP6893608B2 (ja) | 2015-05-29 | 2016-05-26 | がんの処置のためのＰＤ−１アンタゴニストとＣｐＧ−Ｃ型オリゴヌクレオチドの併用 |
| JP2021041014A Active JP7236483B2 (ja) | 2015-05-29 | 2021-03-15 | がんの処置のためのＰＤ－１アンタゴニストとＣｐＧ－Ｃ型オリゴヌクレオチドの併用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021041014A Active JP7236483B2 (ja) | 2015-05-29 | 2021-03-15 | がんの処置のためのＰＤ－１アンタゴニストとＣｐＧ－Ｃ型オリゴヌクレオチドの併用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10751412B2 (enExample) |
| EP (2) | EP3302501B1 (enExample) |
| JP (2) | JP6893608B2 (enExample) |
| KR (1) | KR20180014009A (enExample) |
| CN (1) | CN108025018B (enExample) |
| AU (1) | AU2016271018A1 (enExample) |
| BR (1) | BR112017025562A2 (enExample) |
| CA (1) | CA2986126A1 (enExample) |
| ES (1) | ES2985394T3 (enExample) |
| MA (1) | MA44699A (enExample) |
| MX (1) | MX2017015308A (enExample) |
| RU (1) | RU2017145558A (enExample) |
| WO (1) | WO2016196173A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| DK2972193T3 (da) | 2013-03-13 | 2020-03-23 | Univ Miami | Fremgangsmåde til isolation og oprensning af mikrovesikler fra cellekultursupernatanter og biologiske fluider |
| US12558316B2 (en) | 2013-03-13 | 2026-02-24 | University Of Miami | Methods and compositions for the treatment of epidermolysis bullosa |
| US20160101128A1 (en) | 2014-10-10 | 2016-04-14 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonist with checkpoint inhibitors |
| US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| LT3240801T (lt) * | 2014-12-31 | 2021-02-25 | Checkmate Pharmaceuticals, Inc. | Kombinuota navikų imunoterapija |
| BR112017025562A2 (pt) | 2015-05-29 | 2018-08-07 | Merck Sharp & Dohme Corp. | métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| JP7200093B2 (ja) | 2016-09-15 | 2023-01-06 | アイデラ・ファーマシューティカルズ，インコーポレーテッド | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 |
| WO2018201028A1 (en) | 2017-04-28 | 2018-11-01 | Merck Sharp & Dohme Corp. | Biomarkers for cancer therapeutics |
| AU2018263868A1 (en) | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
| KR20200068655A (ko) | 2017-10-13 | 2020-06-15 | 머크 샤프 앤드 돔 코포레이션 | 미만성 거대 b 세포 림프종의 치료를 위한 조성물 및 방법 |
| WO2019084418A1 (en) | 2017-10-27 | 2019-05-02 | Merck Sharp & Dohme Corp. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER CANCER |
| US12246031B2 (en) | 2018-02-13 | 2025-03-11 | Checkmate Pharmaceuticals, Inc. | Compositions and methods for tumor immunotherapy |
| MX2020010410A (es) | 2018-04-09 | 2021-01-15 | Checkmate Pharmaceuticals | Empaquetado de oligonucleotidos en particulas similares a virus. |
| WO2019200238A1 (en) * | 2018-04-14 | 2019-10-17 | Dynavax Technologies Corporation | Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer |
| WO2020081398A1 (en) * | 2018-10-14 | 2020-04-23 | Dynavax Technologies Corporation | Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer |
| CN113015748B (zh) | 2018-10-31 | 2025-12-12 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| CN113316458B (zh) * | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| WO2020119728A1 (zh) * | 2018-12-12 | 2020-06-18 | 尚华科创投资管理（江苏）有限公司 | 抗人白细胞介素5(il-5)单克隆抗体及其应用 |
| CN111321159B (zh) * | 2018-12-14 | 2023-12-12 | 中天(上海)生物科技有限公司 | 用于免疫调节的嵌合核酸分子及其应用 |
| EP3845649B1 (en) * | 2019-12-31 | 2025-09-24 | Industrial Technology Research Institute | Nucleic acid-drug complex and use thereof |
| CN114981436A (zh) * | 2020-01-10 | 2022-08-30 | Sbi生物技术有限公司 | 新tlr9激动剂 |
| CA3189834A1 (en) * | 2020-07-24 | 2022-01-27 | Ronald Levy | A three component vaccine for covid-19 |
| EP4217064A4 (en) * | 2020-09-22 | 2024-08-07 | TriSalus Life Sciences, Inc. | CANCER THERAPY WITH TOLL-LIKE RECEPTOR AGONISTS |
| JP2023542989A (ja) * | 2020-09-22 | 2023-10-12 | トリサルース・ライフ・サイエンシズ・インコーポレイテッド | トール様受容体アゴニストを使用したがん治療 |
| CN116685330A (zh) * | 2020-09-22 | 2023-09-01 | 特萨乐斯生命科学公司 | 使用toll样受体激动剂的癌症疗法 |
| WO2022110010A1 (zh) * | 2020-11-27 | 2022-06-02 | 苏州吉玛基因股份有限公司 | 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用 |
| KR20240004419A (ko) * | 2021-04-01 | 2024-01-11 | 트라이살루스 라이프 사이언시즈, 인크. | 톨-유사 수용체 작용제를 사용한 암 요법 |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| US20250009731A1 (en) | 2021-11-08 | 2025-01-09 | Nurix Therapeutics, Inc. | Toll-like receptor therapy combinations with cbl-b inhibitor compounds |
| JP2026504180A (ja) | 2023-01-30 | 2026-02-03 | カイマブ・リミテッド | 抗体 |
| WO2025233224A1 (en) | 2024-05-09 | 2025-11-13 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with anti-pd(l)1 therapy |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6217857B1 (en) | 1989-06-28 | 2001-04-17 | Schering Corporation | Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof |
| CA2244946C (en) | 1996-01-30 | 2010-04-13 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
| EP0930893B1 (en) | 1996-10-11 | 2005-04-13 | The Regents of The University of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| JP4101888B2 (ja) | 1997-06-06 | 2008-06-18 | ダイナバックス テクノロジーズ コーポレイション | 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法 |
| EP1009413B1 (en) | 1997-09-05 | 2007-02-14 | The Regents Of The University Of California | Use of immunostimulatory oligonucleotides for preventing or treating asthma |
| CA2352572C (en) | 1998-12-01 | 2010-04-20 | Abbvie Biotherapeutics Inc. | Humanized antibodies to gamma-interferon |
| EP1176966B1 (en) | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynucleotide and its use to induce an immune response |
| AU2002231336B2 (en) | 2000-12-27 | 2007-06-28 | Surefire Medical, Inc. D/B/A Trisalus Life Sciences | Immunomodulatory polynucleotides and methods of using the same |
| EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| ES2381309T3 (es) | 2002-12-23 | 2012-05-25 | Dynavax Technologies Corporation | Secuencia de oligonucleótidos inmunoestimuladores y métodos para usar los mismos |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| PE20050925A1 (es) | 2003-11-10 | 2005-11-29 | Schering Corp | Anticuerpo recombinante humanizado anti-interleuquina 10 |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| CN101490085A (zh) * | 2006-06-12 | 2009-07-22 | 特鲁比昂药品公司 | 具有效应功能的单链多价结合蛋白 |
| JP5191537B2 (ja) * | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP2328920A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| ES2738700T3 (es) * | 2009-02-13 | 2020-01-24 | Immunomedics Inc | Inmunoconjugados con un enlace escindible intracelularmente |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| WO2012006634A2 (en) * | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
| CA2830806C (en) | 2011-03-31 | 2020-05-12 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| EA026924B1 (ru) * | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
| RU2689760C2 (ru) * | 2012-05-31 | 2019-05-30 | Дженентек, Инк. | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| EP2981821B2 (en) * | 2013-04-02 | 2021-11-03 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| CN105682683A (zh) | 2013-08-02 | 2016-06-15 | 阿杜罗生物科技控股有限公司 | 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激 |
| JP2016534044A (ja) * | 2013-10-11 | 2016-11-04 | ジェネンテック， インコーポレイテッド | 癌の免疫療法のためのｃｂｐ／ｅｐ３００ブロモドメインインヒビターの使用 |
| EP3136858A4 (en) | 2014-05-02 | 2018-01-03 | Nitor Therapeutics | Guanosine as an immunepotentiator mediated through toll receptors |
| US20160101128A1 (en) * | 2014-10-10 | 2016-04-14 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonist with checkpoint inhibitors |
| LT3240801T (lt) | 2014-12-31 | 2021-02-25 | Checkmate Pharmaceuticals, Inc. | Kombinuota navikų imunoterapija |
| US20180161427A1 (en) | 2015-05-29 | 2018-06-14 | Merck Sharp & Dohme Corp. | Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer |
| BR112017025562A2 (pt) | 2015-05-29 | 2018-08-07 | Merck Sharp & Dohme Corp. | métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer |
-
2016
- 2016-05-26 BR BR112017025562A patent/BR112017025562A2/pt not_active Application Discontinuation
- 2016-05-26 ES ES21159163T patent/ES2985394T3/es active Active
- 2016-05-26 WO PCT/US2016/034275 patent/WO2016196173A1/en not_active Ceased
- 2016-05-26 MA MA044699A patent/MA44699A/fr unknown
- 2016-05-26 CA CA2986126A patent/CA2986126A1/en not_active Abandoned
- 2016-05-26 US US15/577,369 patent/US10751412B2/en active Active
- 2016-05-26 EP EP16804054.1A patent/EP3302501B1/en active Active
- 2016-05-26 KR KR1020177037185A patent/KR20180014009A/ko not_active Withdrawn
- 2016-05-26 CN CN201680043989.1A patent/CN108025018B/zh active Active
- 2016-05-26 EP EP21159163.1A patent/EP3892284B1/en active Active
- 2016-05-26 MX MX2017015308A patent/MX2017015308A/es unknown
- 2016-05-26 RU RU2017145558A patent/RU2017145558A/ru not_active Application Discontinuation
- 2016-05-26 AU AU2016271018A patent/AU2016271018A1/en not_active Abandoned
- 2016-05-26 JP JP2017561621A patent/JP6893608B2/ja active Active
-
2020
- 2020-08-21 US US17/000,149 patent/US11918648B2/en active Active
-
2021
- 2021-03-15 JP JP2021041014A patent/JP7236483B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516911A5 (enExample) | ||
| JP2021102627A5 (enExample) | ||
| RU2017145558A (ru) | Комбинация антагониста pd-1 и олигонуклеотида типа cpg-c для лечения рака | |
| JP2017524715A5 (enExample) | ||
| RU2017117664A (ru) | Комбинация | |
| Lote et al. | PD-1 and PD-L1 blockade in gastrointestinal malignancies | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| JP2015532292A5 (enExample) | ||
| WO2015112805A8 (en) | Human antibodies to pd-l1 | |
| JP2017506264A5 (enExample) | ||
| JP2019524701A5 (enExample) | ||
| JP2018008963A5 (enExample) | ||
| IL276515B1 (en) | PD–L1-specific antibodies and methods of using them | |
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| NZ600281A (en) | Compositions and methods for the treatment of infections and tumors | |
| HRP20210440T1 (hr) | Kombinirana terapija za rak | |
| HRP20241325T1 (hr) | Kombinirana terapija za melanom | |
| IL278423B1 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| JP2018518454A5 (enExample) | ||
| RU2016104880A (ru) | Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit | |
| JP2020502271A5 (enExample) | ||
| JP2018508512A5 (enExample) | ||
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| HRP20212033T1 (hr) | Anti-lag-3 antitijela za liječenje hematoloških maligniteta |